Lung Monitoring Devices Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Product Type (Spirometers, Pulse Oximeters, Capnographs, Others), By End User (Hospitals & Clinics, Ambulatory Care Centers, Others), By Region and Competition 2021-2031F

Forecast Period	2027-2031
Market Size (2025)	USD 4.16 Billion
CAGR (2026-2031)	6.62%
Fastest Growing Segment	Spirometers
Largest Market	North America
Market Size (2031)	USD 6.11 Billion

Market Overview

The Global Lung Monitoring Devices Market will grow from USD 4.16 Billion in 2025 to USD 6.11 Billion by 2031 at a 6.62% CAGR. Lung monitoring devices are specialized diagnostic and therapeutic instruments utilized to assess respiratory parameters such as lung capacity, gas exchange, and airflow obstruction for the effective management of pulmonary conditions. The primary drivers fueling market growth include the escalating prevalence of chronic respiratory disorders and the expanding geriatric population susceptible to lung ailments. According to the International Pharmaceutical Federation, in 2024, it was reported that 391 million people globally were living with chronic obstructive pulmonary disease. This rising disease burden creates an urgent demand for accurate assessment tools to mitigate long-term health complications and supports the sustained adoption of these devices across healthcare facilities.

One significant challenge hampering the broad expansion of this market is the high acquisition cost of advanced monitoring systems coupled with inadequate reimbursement structures in emerging economies. These financial constraints limit the accessibility of modern respiratory care technologies for healthcare providers in low-income regions and potentially stifle market penetration despite the growing clinical necessity for respiratory health management.

Key Market Drivers

Technological innovations in smart and wearable monitoring devices are revolutionizing the Global Lung Monitoring Devices Market by enhancing diagnostic accuracy and patient convenience. The integration of artificial intelligence and contactless sensors allows for continuous assessment of respiratory function without cumbersome hardware, addressing the industry's pivot toward accessible solutions for non-invasive monitoring. For instance, according to Mindset Medical, June 2025, in the 'Mindset Medical Announces FDA Clearance for its Contactless Respiratory Rate Measurement Device' press release, the company received clearance for a software-only application that measures respiratory rates via standard smartphone cameras. This advancement exemplifies how digital health tools are removing barriers to entry and facilitating widespread adoption of respiratory tracking technologies across diverse patient demographics.

Concurrently, the shift toward remote patient monitoring and home healthcare is significantly expanding market opportunities as healthcare systems seek to reduce hospital admissions. This trend is driven by the increasing need to manage chronic conditions outside traditional clinical settings, exacerbated by deteriorating environmental factors. According to the American Lung Association, in 2025, approximately 156 million people in the U.S. were living in areas with unhealthy levels of air pollution, contributing to the sustained demand for home-based management solutions. Consequently, major market players are seeing robust financial growth from these decentralized care models; according to ResMed, July 2025, in the 'ResMed Inc. Announces Results for the Fourth Quarter of Fiscal Year 2025' report, the company reported a 10% revenue increase to $1.3 billion, underscoring the commercial viability and rising adoption of remote respiratory care technologies.

Download Free Sample Report

Key Market Challenges

The high acquisition costs of advanced monitoring systems, combined with inadequate reimbursement structures, significantly restrict the expansion of the Global Lung Monitoring Devices Market. Healthcare facilities, particularly in emerging economies, often face substantial capital limitations that prevent them from investing in modern diagnostic equipment. This barrier is further compounded when insurers and public health programs provide insufficient coverage for these technologies, effectively making advanced respiratory care financially unviable for many providers. Consequently, hospitals are forced to forgo necessary equipment upgrades, which directly stifles the adoption rate of precise monitoring tools and limits market penetration in regions where respiratory burdens are often highest.

This lack of financial accessibility not only hampers market revenue but also perpetuates inefficiencies in patient care, leading to significant economic losses. The inability to deploy these devices contributes to missed diagnoses and poor disease management. According to the European Respiratory Society, in 2025, it was reported that the underdiagnosis and misdiagnosis of chronic respiratory diseases cost the European region an estimated $21 billion annually. This substantial figure illustrates how financial constraints and funding gaps impede the widespread integration of monitoring solutions, thereby preventing the market from reaching its full growth potential while exacerbating the long-term economic burden on healthcare systems.

Key Market Trends

The Development of Multi-Parameter Cardio-Respiratory Devices is transforming the market by consolidating distinct diagnostic functions into compact, clinical-grade tools for holistic health assessment. Manufacturers are increasingly engineering devices that simultaneously track pulmonary and cardiovascular metrics, recognizing the critical interplay between heart and lung function in chronic disease management. This convergence eliminates the need for multiple disparate gadgets, thereby streamlining the patient experience and improving the quality of comprehensive data available to clinicians for remote evaluation. According to Withings, November 2025, in the 'Withings Redefines At-Home Family Healthcare in the US with FDA Clearance of BeamO' press release, the company received FDA clearance for its new 4-in-1 multiscope device which combines a digital stethoscope, electrocardiogram, and oximeter into a single handheld unit retailing for $249.95.

Concurrently, the Adoption of Smart Connected Inhalers and Nebulizers is gaining momentum as the industry prioritizes medication adherence and data-driven therapeutic management over passive drug delivery. These next-generation delivery systems are integrating with digital health ecosystems to bridge the gap between patients and providers, ensuring that respiratory treatments are administered correctly and monitored in real-time. This improved connectivity supports proactive intervention strategies that prevent disease progression and significantly reduce the burden on acute care facilities. According to Omron Healthcare, October 2025, in the 'OMRON Healthcare Surpasses 50 Million Nebulizers Sold' announcement, the company reported that cumulative sales of its nebulizers had surpassed 50 million units, a milestone that underscores the massive global scale and growing reach of these respiratory management solutions within connected care networks.

Segmental Insights

The spirometers segment is currently positioned as the fastest growing category within the global lung monitoring devices market. This expansion is primarily driven by the rising prevalence of chronic respiratory conditions such as asthma and COPD which necessitate frequent pulmonary function testing for effective disease management. Furthermore, the market is witnessing a significant shift towards home healthcare, supported by the development of portable devices that facilitate remote patient monitoring. Regulatory bodies like the U.S. FDA contribute to this growth by granting approvals for advanced digital spirometry solutions, thereby increasing adoption rates among healthcare providers and patients.

Regional Insights

North America holds the leading position in the Global Lung Monitoring Devices Market, primarily due to its well-established healthcare infrastructure and high adoption of digital monitoring technologies. The region faces a significant burden of chronic respiratory conditions, as highlighted by data from the American Lung Association, which drives sustained demand for effective diagnostic tools. This market growth is further supported by a structured regulatory environment under the U.S. Food and Drug Administration, facilitating the timely approval of new medical devices. Additionally, comprehensive reimbursement policies and the presence of major manufacturers solidify the region's market dominance.

Recent Developments

• In August 2025, Strados Labs announced a series of new research collaborations with several academic institutions to evaluate the clinical utility of its RESP Biosensor in various care settings. The studies aim to assess how continuous, objective monitoring of lung sounds—such as coughing, wheezing, and crackles—can improve patient outcomes and aid in the early detection of complications like pulmonary edema. One key collaboration involves Beth Israel Deaconess Medical Center, where researchers will investigate the device's ability to identify abnormal lung sounds in critically ill patients on mechanical ventilation. These initiatives seek to validate the wearable device's potential to support proactive respiratory management in both hospital and home environments.
• In May 2025, ZEPHYRx and ActiGraph announced a strategic partnership to enhance remote monitoring capabilities for respiratory clinical trials. This collaboration integrates ZEPHYRx’s respiratory cloud platform and remote spirometry solutions with ActiGraph’s wearable technology and scientific services, creating a comprehensive digital health solution for collecting real-world data. The partnership is designed to improve the accuracy and efficiency of capturing respiratory endpoints, such as lung function and behavioral data, from patients in decentralized trial settings. By combining these technologies, the companies aim to streamline data collection for researchers and reduce the burden on patients participating in studies for respiratory drug development.
• In November 2024, 4DMedical entered into a significant commercial agreement with Imaging Partners of Orange County, following an expanded distribution partnership with Philips. Under the terms of the broader collaboration with the multinational health technology company, 4DMedical secured a minimum US$10 million order commitment for its respiratory imaging solutions. This agreement focuses on the distribution of the company's advanced lung scanning technologies, including the CT:VQ imaging system, to healthcare providers in the United States. The deal aims to accelerate the commercial adoption of these non-invasive lung function analysis tools, which provide detailed insights into airflow and blood flow within the lungs using existing computed tomography infrastructure.
• In January 2024, NuvoAir Medical received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its Air Next spirometer, approving the device for home use as a fully functioning diagnostic tool. This regulatory approval enables the company to conduct clinical-grade spirometry testing in a patient's home, facilitating the continuous monitoring of lung function for individuals with chronic conditions such as chronic obstructive pulmonary disease (COPD) and asthma. The clearance supports a virtual-first care model, allowing clinical teams to access high-quality data remotely and intervene promptly when respiratory changes are detected, thereby potentially preventing hospitalizations.

Key Market Players

• Baxter International Inc.
• Becton, Dickinson and Company
• ICU Medical Inc.
• Koninklijke Philips N.V.
• Masimo Corporation
• Medtronic plc
• Nihon Kohden Corporation
• ResMed Inc.
• Teleflex Incorporated.
• Vyaire Medical, Inc.

By Product Type	By End User	By Region
Spirometers Pulse Oximeters Capnographs Others	Hospitals & Clinics Ambulatory Care Centers Others	North America Europe Asia Pacific South America Middle East & Africa

Report Scope:

In this report, the Global Lung Monitoring Devices Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Lung Monitoring Devices Market, By Product Type:

• Spirometers
• Pulse Oximeters
• Capnographs
• Others

• Lung Monitoring Devices Market, By End User:

• Hospitals & Clinics
• Ambulatory Care Centers
• Others

• Lung Monitoring Devices Market, By Region:

• North America
• United States
• Canada
• Mexico
• Europe
• France
• United Kingdom
• Italy
• Germany
• Spain
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• South America
• Brazil
• Argentina
• Colombia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE